BRIEF

on CEGEDIM (EPA:CGM)

Cegedim's First-Half 2026 Results: Continued Profitability Growth

Stock price chart of CEGEDIM (EPA:CGM) showing fluctuations.

Cegedim's first-half results for 2026 show sustained improvement in profitability, with consolidated revenue hitting €324.8 million, marking a slight 0.8% rise versus the previous year. The company reported an adjusted EBITDA of €62.0 million, up by 1.3%, equating to 19.1% of total revenue. This growth was underpinned by strategic reductions in external service use and streamlined payroll following a restructuring in the pharmacy software business in France.

The firm's adjusted operating income increased to €19.7 million, a 6.9% increment from the prior year, while its operating income surged to €17.3 million, up 82.9%. Cegedim's strategic focus on artificial intelligence enhanced internal productivity and enriched client offerings, including AI integration in various business units.

Despite challenges, such as a decline in the Healthcare Professionals sector, other divisions like Business Services and Health & Provident Insurance saw notable growth. The company remains optimistic about exceeding 2% like-for-like revenue growth for the full year.

R. E.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all CEGEDIM news